Видео ютуба по тегу Biocon Growth Forecast

BIOCON: Искусственный интеллект прогнозирует влияние инновационного процесса на выручку после 202...
BIOCON: Искусственный интеллект прогнозирует влияние инновационного процесса на выручку после 202...
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
CEO of India's Biocon discusses first-quarter results
CEO of India's Biocon discusses first-quarter results
SP Tulsian's Take on Biocon Sotck | Numbers in-line with Estimates; Growth of 20% | CNBC TV18
SP Tulsian's Take on Biocon Sotck | Numbers in-line with Estimates; Growth of 20% | CNBC TV18
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biologics Business Lifts Biocon’s Upbeat Quarter: #Q3WithBQ
Biologics Business Lifts Biocon’s Upbeat Quarter: #Q3WithBQ
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Posts Healthy Numbers In Q4
Biocon Posts Healthy Numbers In Q4
How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
Biocon - A simple analysis of 2Q results and road ahead!
Biocon - A simple analysis of 2Q results and road ahead!
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Q4 Below Estimates
Biocon Q4 Below Estimates